摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴乙基甲基砜 | 16523-02-7

中文名称
2-溴乙基甲基砜
中文别名
1-溴-2-(甲基磺酰基)乙烷
英文名称
1-bromo-2-(methylsulfonyl)ethane
英文别名
2-bromoethyl methyl sulfone;2-bromoethyl methyl sulphone;1-bromo-2-(methanesulfonyl)ethane;1-bromo-2-methylsulfonylethane
2-溴乙基甲基砜化学式
CAS
16523-02-7
化学式
C3H7BrO2S
mdl
MFCD08274926
分子量
187.057
InChiKey
NIEGKADUBXVLHF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    126-128 °C(Press: 3.5 Torr)
  • 密度:
    1.666±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    7
  • 可旋转键数:
    2
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    42.5
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2904909090
  • 包装等级:
    III
  • 危险类别:
    8
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险品运输编号:
    1759
  • 危险性描述:
    H315,H318,H335

SDS

SDS:397ad8258fbab0948b6a58d134753f0a
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Bromoetyl-methylsulfone
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromoetyl-methylsulfone
CAS number: 16523-02-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C3H7BrO2S
Molecular weight: 187.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    2-溴乙基甲基砜 作用下, 以 乙醇 为溶剂, 生成 (2-Methanesulfonylethyl)hydrazine
    参考文献:
    名称:
    9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS
    摘要:
    本公开提供了代表为式I的替代的9H-嘧啶并[4,5-b]吲哚和5H-吡啶并[4,3-b]吲哚及相关类似物的药用可接受的盐、水合物和溶剂合物,其中R1a、A、B1、B2、G、X1、Y1、Y2和Y3如规范中所定义。本公开还涉及使用式I的化合物来治疗对BET溴结构域抑制敏感的状况或疾病。本公开的化合物特别适用于治疗癌症。
    公开号:
    US20150246923A1
  • 作为产物:
    描述:
    2-溴乙基甲基硫醚双氧水硼酸 作用下, 以 四氢呋喃 为溶剂, 以14.6 g的产率得到2-溴乙基甲基砜
    参考文献:
    名称:
    化合物、液晶组合物、液晶显示元件及液晶显示器
    摘要:
    本发明涉及化合物、液晶组合物、液晶显示元件及液晶显示器。所述化合物为下述的式I所示的化合物。本发明的液晶组合物含有式I所示的化合物。本发明提供的式I所示化合物具有与其他化合物互溶性好、紫外线耐受能力好等优点。作为反应性介晶(RM)具有互溶性良好、电荷保持率(VHR)高、聚合活性高(单体残留少)等优点,不仅可以单独作为液晶组合物的自配向剂,也可以于作为垂直配向材料与其他RM共聚用于PSA(聚合物支持的配向)、PS(聚合物稳定的)型模式的液晶组合物的自配向剂,可以避免PI制程,使液晶显示元件或液晶显示器的制程得到简化,提高生产效率。
    公开号:
    CN110804005A
点击查看最新优质反应信息

文献信息

  • [EN] COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK<br/>[FR] COMBINAISONS D'INHIBITEURS DE L'IRAK4 À L'AIDE D'INHIBITEURS DE LA BTK
    申请人:BAYER PHARMA AG
    公开号:WO2016174183A1
    公开(公告)日:2016-11-03
    The present application relates to novel combinations of at least two components, component A and component B: · component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; · component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, · one or more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.
    本申请涉及至少两种组分的新型组合,组分A和组分B:·组分A是根据本文所定义的式(I)的IRAK4抑制化合物,或其对映体、对映异构体、代谢物、盐、溶剂合物或其盐的溶剂合物;·组分B是BTK抑制化合物,或其药学上可接受的盐;以及,可选地,·一种或多种组分C,它们是药用产品;其中上述定义的化合物A和B中的一种或两种可选择地存在于用于治疗和/或预防疾病的制剂中,准备用于同时、分开或顺序给药,用于治疗和/或预防疾病,以及用于生产用于治疗和/或预防疾病的药物的用途,特别是用于治疗和/或预防子宫内膜异位症、淋巴瘤、黄斑变性、慢性阻塞性肺病、肿瘤性疾病和牛皮癣。
  • [EN] SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY<br/>[FR] DIHYDROPYRIMIDINONES BICYCLIQUES SUBSTITUÉES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE L'ACTIVITÉ ÉLASTASE DE NEUTROPHILES
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2014135414A1
    公开(公告)日:2014-09-12
    This invention relates to substituted bicyclic dihydropyrimidinones of formula (1) and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
    这项发明涉及式(1)的取代双环二氢嘧啶酮及其作为中性粒细胞弹性蛋白酶活性抑制剂的用途,含有这些化合物的药物组合物,以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药剂的方法。
  • [EN] PIPERIDINES OR PIPERIDONES SUBSTITUTED WITH UREA AND PHENYL<br/>[FR] PIPÉRIDINES OU PIPÉRIDONES SUBSTITUÉES PAR DE L'URÉE ET DU PHÉNYLE
    申请人:GRUENENTHAL GMBH
    公开号:WO2019170904A1
    公开(公告)日:2019-09-12
    The present invention relates to a compound according to general formula (I) which acts as a modulator of FPR2 and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by FPR2.
    本发明涉及一种符合一般式(I)的化合物,该化合物作为FPR2的调节剂,并可用于治疗和/或预防至少部分由FPR2介导的疾病。
  • [EN] ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS<br/>[FR] ARYLOXYACÉTYLINDOLES ET ANALOGUES EN TANT QU'INHIBITEURS DE TOLÉRANCE AUX ANTIBIOTIQUES
    申请人:SPERO THERAPEUTICS INC
    公开号:WO2016112088A1
    公开(公告)日:2016-07-14
    The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.
    该披露提供了芳基氧乙酰基吲哚化合物及类似物的化合物和药物组合物,用于治疗慢性和急性细菌感染。其中某些化合物是一般式(I)(I)的化合物或其药用可接受的盐或前药。该披露的某些化合物是MvfR抑制剂。MvfR抑制剂减少抗生素耐药细菌菌株的形成,对治疗革兰氏阴性细菌感染和减少铜绿假单胞菌的毒力有用。该披露还提供了治疗受试者细菌感染的方法,包括铜绿假单胞菌感染。
  • [EN] HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
    申请人:ARTIOS PHARMA LTD
    公开号:WO2021028643A1
    公开(公告)日:2021-02-18
    The application relates to heterocyclic amide derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation. (Formula (I))
    该申请涉及杂环酰胺衍生物及其在癌症治疗和预防中的应用,以及含有这些衍生物的组合物和其制备方法。(化学式(I))
查看更多